Generic Drug Market Entry in Europe: Why a Tailored Approach Is Best

June 10, 2019 | 165 views

Many government and healthcare authorities across Europe are concerned about rising pharmaceutical prices, and they increasingly promote the use of generics over branded drugs when possible. This is good news for companies interested in generic drug market entry in Europe.

Spotlight

Eden Healthcare Solutions

At Eden Healthcare Solutions, we specialize in providing equipment to hospitals, special schools and aged care facilities. We also have a showroom open to the public and a wide range of equipment designed to help elderly people remain independent in their own homes. We value honest, open, two-way communication, working to build long-term relationships with a deep understanding of our client’s needs.

OTHER ARTICLES
PHARMA TECH

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | October 6, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
PHARMA TECH

What are the advantages of PCD Pharma Company?

Article | July 12, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More
PHARMA TECH

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | July 20, 2022

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Eden Healthcare Solutions

At Eden Healthcare Solutions, we specialize in providing equipment to hospitals, special schools and aged care facilities. We also have a showroom open to the public and a wide range of equipment designed to help elderly people remain independent in their own homes. We value honest, open, two-way communication, working to build long-term relationships with a deep understanding of our client’s needs.

Related News

Short sellers eye Teva and Mylan as U.S. generics market troubles persist, analyst says

Teva | July 31, 2017

How bad is the generics market in the U.S. these days? Reports from some players are that it continues to be tough, but the picture will get a lot clearer when generics leader Teva reports Thursday, followed by Mylan next week. Indications are the short sellers are tuned in. Novartis provided an inkling of how competitive the U.S. generics remains when it reported last month that sales at its Sandoz generics unit were down 4%. Bernstein analyst Ronny Gal told investors in a note today that he has gotten some short seller calls about Mylan and Teva and “much of the short thesis” is based on Sandoz’ difficulties, as well as results from India’s Dr. Reddy’s, which last week talked about pricing in the U.S. being down 10% to 20% in the quarter.

Read More

Teva Pharmaceuticals has acquired success with Actavis Generics

Teva Pharmaceuticals | December 26, 2016

The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of the firm, Teva’s dealmakers coupled two leading generics businesses with complementary strengths, research and development capabilities, product pipelines and portfolios while matching their geographical footprints, operational networks and cultures…

Read More

Short sellers eye Teva and Mylan as U.S. generics market troubles persist, analyst says

Teva | July 31, 2017

How bad is the generics market in the U.S. these days? Reports from some players are that it continues to be tough, but the picture will get a lot clearer when generics leader Teva reports Thursday, followed by Mylan next week. Indications are the short sellers are tuned in. Novartis provided an inkling of how competitive the U.S. generics remains when it reported last month that sales at its Sandoz generics unit were down 4%. Bernstein analyst Ronny Gal told investors in a note today that he has gotten some short seller calls about Mylan and Teva and “much of the short thesis” is based on Sandoz’ difficulties, as well as results from India’s Dr. Reddy’s, which last week talked about pricing in the U.S. being down 10% to 20% in the quarter.

Read More

Teva Pharmaceuticals has acquired success with Actavis Generics

Teva Pharmaceuticals | December 26, 2016

The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of the firm, Teva’s dealmakers coupled two leading generics businesses with complementary strengths, research and development capabilities, product pipelines and portfolios while matching their geographical footprints, operational networks and cultures…

Read More

Events